Company wislralion number.. 08116159 Charity registration number." 1148845 ALEX'S WISH TRUSTEES, REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 Sturge$s Hutchin$ Al*x'$ Wish Contents Page Trustees, Report Independent Examinels Report 18 Slolemenl of Financial AdNities (including Irwne and Expendilufe A￿UntI 19 Balance Sheet 20 Notes lo the Financiol Statements 21-26 The foifowing pages do not form part of the slalulory xcounts.. Detailed Statement of Financial Aclmties (including IrKcrfne and Expendrture Account) Alex's Wish Company No. 08116159 Trustees. Report For The Year Ended 30 Jun• 2025 The Iruslees present their report and the financial statements for the year ended 30 June 2025. ObJ¢¢tlvos and A¢tlvltles Alms and ObjKtives 1. The principal objgcts of th• charitable company are the rell•l of slcknèss and the preservatlon of good health by supporting scientific research Into the improved dlagnosls. preventlon. or trnatmènt of Du¢honn• Muscular Dystrophy by- al Extending the current scope of drugs I treatments so that they will help all children with Duchenne Muscular Dystrophy. bl Fund first stage clinical trials that proV￿e the safety and efficacy of some of these treatments and then progress this into larger scale production. cl Fund the completion of scientific work already begun, lo bring il lo clinical Inals, and tund other fornis of Irealmènl that will work on all children regardless of their genelic mulalion. dl Fund slLtrdies that will bnng about data and information lo help d¢ci$ion makers make decisions on which Ifealments lo bring to market. el Fund the DMO Care programme empwering patientsrtamilies to access the best care wherèver they live in the UK. fj Fund new techno1c9￿aJ advances lo he4) children and young adutts Irving with Duchgnne live a beller quality of lrfè. 2. Advance the frducatlon ot th• publlc In all areas relatlng to Duch•nn• MU￿ul•r Dystrophy by dlssemln*tlng Inlormatlon on the dlsoase and its treatments and ¢urgs. To: al Disseminate information using online and offline malenals, including tho Abgx's Wtsh Websrte and via oui monthly e-newsletters lo our supporters. bl Running events and fundraising activrties, Including our Spring Launch and Autumn Lunch which sees our team. trustees, represenlalives ftom Duchenne UK, and our supporters come together for us to share our impact during the last 12 month$ and our plans. cl Promoting our work across a vanety of s(Kial media platlomis. incIL￿1ft9 Facebook. You Tube, Linkedin, Insla9ram and Tik Tok. dl We have buitt great relationships wrth the local media Qui￿1$ in our region including ITV Central and BBC East Midlands and regularly generate new$ articks ènd updates in lo￿1 newspapers, including The Leicester Mercury. The Loughborou9h Echo and local magazines posted through door5. We appear regularly on the local radio slalions including BBC Radio Le￿¢Ster to raise awareness aboul Duchenne and thè impact thi5 has on families living with It. el Talking and presenting at various events on Corporate Social Responsibilrty. the impa¢l of living with Duchenne Muscular Dystrophy and About Alex's Wish - it 1$ important our personal Glory is shared amongst others lo be the voice for other lamilie5 affected by Duchenne. f) Owning It 'The Power of Resilience. talks and wortEshops delivered lo busIne￿e$ in exchange for a donation to the charity. SlgnllS¢ant Activiti•s Statement from the CEO and Chanty Founder. Emma HaI￿rn Dear Supporters, Sin¢e we launched Ale*s W￿h in kle 2012, after our son Alex w8$ diagnosed with Duchenne Muscular Dystrophy, we continue lo make great progress. Our relentles$ energy and passK•n inspire us every single day, lo delivef results for the Du¢henne community. We exlst to defeat Du¢henn• lor this generation of children and young adutts. Our approach is simple, fvnd the best scien￿, support practical clinical trials and make sure children and young adutts living with Duchennè in the UK, can access Ireatmenls, r*w technologies and care. wherever they live. ..CONTINUED Page 1 Alex's W￿h Trustees. Report Icontinuedl For The Year Ended 30 June 2025 Slgnlfi¢ant Activbtlgs- conlinu•d We fund across th• treatm•nt lourney - from research to reakwodd care. This ineludes projects ranging from gene therapy and gene edrting, stem cell therapy. heart reSea￿h and early detection. steroid oplimisalion and alternative5, clinical care and improving access lo clinical trials in the UK, improving quality of life through n technologies namely The ELEVEX Suit and The DREAM Vtheekhair, as well as Supporting female carTiers through better understanding the impact this has for them. Since18unch, we have dolivergd.. . Raised over £2.8M Funded 42 projects . Supported 24 medi￿1 research proJ8ds Supported 4 clinical tria15 . Supported S projects improving care in the UK . Supported 7 clinical posts supporting the Du¢henne communty . Supported 2 technology pr¢4ecls lo improve how children and young adults n8vwJate thè wodd whilst living with Duchenne How we docldo what to fund. Every proj•cl is revwrtd by an independent sC￿n11fiC Advisory Board, made up of leading global experts in Duchenne. This en$ure$ that funding only goes lo the best $¢18nce worldwide. No duplication of existing research. Every prtyect has a clear path of delivery. Treatments move faster from the lab lo the patient. Wo work closely wrth Duchenne UK. lo maximise impad and accderale progress. How we got h•ro. Alex's Wlsh was founded by Emma and Andy Hallam after Iheir son Alex was dia9nos8d with Duchgnne shortly before his fourth birthday. Al the lime, support was limited. We were told lo lake Alex hor￿ and live the best life po$$iblo. Long-lerm steroids were the onty Irealmenl option offered. despite significant Gide effects. There was no eure, and little hop8 of modi￿1 breakthroughs. Since Alex's diagnosis in 2010, Emma and a small, deduted team - supported by an incredible community of trustees, amb888adors, supporters, and p8rtners- have W0￿ed tirele88ly lo create real, measurable change. Alex has played his part loo. spending much of his youn9 lrfe taking part in clinical trials that havè hèlped advance treatments and deliver genuine progress. We're deeply grateful to 9￿ryOne who helps make progress po8St¥be. An exC￿￿n9 t5me In medlcal breakthroughs The science is 81 a very exciting lime." a lime of optimism as new Irealmenls have emerged, one of which is proving to be delaying disease piogression. We are aware thal time is not on our side. and that for families affected by Duchenne - whether they have a child diagnosed several year5 ago, or families receiving a recent diagnosis - they need solutions to support thetr chikl. This is what drtves us every single day. lo lundraise and raise awareness lo continue supportsng nthv innovative projacts to address the problems within the Duchenne communty. This financial year, we have been 8ble lo support a further four projects. Vamorolone la stsiold altematlv• drug) 2023 was a bieakthrough year the first ever drug approved for use on ¢hildren with Duchenne ¢alled Vamorolone, thanks lo charities like Aex's Wsh who helped fund the earty stages of this project. When Alex was diagnosed back in 2010. we were told the slandaid medication for chIld￿n wrth Duchenne. steroids, would keep them independenlty mobile for longer. bul wrth hamiful s￿e effeds. Vamorolone a new Steroid drug, th81 h85 less h8mful side*ffecls lo traditional steroids, has been approved by the Medicine5 and Heatthcare produ¢t$ Regulatory Agenw IMHRAI in the UK. We are incredibty proud that we were able to invest in the earty stages lo make this a realty proof that Alex'5 Wish is a charity that is making a positive impact for this generation ol childfen and young adutts IT￿n9 wrth Duchenne. ..CONTINUED Page 2 Alex's Wlsh Trustvs. Report lcontinuedl For The Year Ended 30 June 2025 Slgnlflcant Actrvities - continu8d Glvino$tat (provin9 to delay disease pro9ressionl 2024 was another breakthrough year- Gwinoslal. a drug lo help delay disease progress has been conditionally approved in the UK by MHRA. but it is not yel readity available through the NHS. It is an 'HDAC inhibrtor., il blocks enzyme5 called histone deacetylases, which are invofved in turning genes 'on' and 'off within cells lo help reduce inflammation and muscle loss. Work is underway lo hopefulty gel this drug approved by NICE so that every child and young adutt living with Duchenne can access this drug through the NHS. In the meantime, this drug has been offered free of charge In the UK through the earty access programme. However. il has been the decision of each hospital trust lo decide whether they will provide il lo their Duchenne community. Some have, and Some slill haven't. Duchenne UK and the Duchenne communrty has been working incredibly hard mpaignin9 for a¢ce$$ o¢ros$ the UK. We have been supporting NICE as a patient represenlalive, offering insights into why gaining access to this drug is so important. Whilst Alex'$ Wish did not directly financial contribute towards this projecl. as a family we have been tsking part in the clinical trial over several years. Gen• Th•rapy We were told that Gene Therapy wouldnl happen in our son's lrfelime. During the time that Alex's Wish ha$ bèen in operation, we supported Solid Biosciences, a start-up to pur$ue this new t￿hnolOgY, and boys are now being dosed with gene therapy in clinical trials taking place now in the UK. We know there are Challenges with Gene Therapy. which is why we are continuing lo support projects that are looking lo address these problems - and bring better therapies lo our children. Bèst practlce In Duchenne care We are working alongside DMD ca￿ UK. to help support better qu81ty of care for everyone liwng wrth Duchenne in the UK. To date. wfj have fvnded several projects. including fi'nancial support lor a DMD Hub Project Manager designed lo increase clinical trial capacty in the UK and, a nutrrt￿n programme supporting those affected by Duchenne, and a project k)oking lo address the lack of accessib￿ housing arnongsl our community. This financial year, we have supporte¢J a transitioning project. supporting young adulls living wrth Duchenne during the transitioning stage when they move from Paed￿1￿C care Into adum services- somgthing which we have iecenlly encountered ourselves with Alex. We are incredibly posrtive about Ihe fulure and Ale￿5 Wish gTves us ho￿. Ouchenne Muscular Dystrophy i¥ part of our lives, not out of choKo, but we wll make it 8$ best as we cgn. and we will never slop our journey lo conquering Duchenne. I continue lo support this important cause, by working volunt•rlty for thè charity and as a very proud Irusle& and CEO- rt is my pleasure lo do this. lo support all famil*s affected by Duchenne. Our work is onty possible. thanks to our amiy of supporters. Ihe charitable foundations who 8UPPOrt us, the local business community, our business sponsois, our small team. our patron, ambassadors and our dedicated Iruslees and we would like to thank every single one of them. Thanks for everything you do. Emma Hallam Charity Founderand CEO Publ1¢ Benellt The Charty has established its grant making policy lo achieve rts objectives for the public benefit lo find a cure for Duchenne Muscular Dystrophy and lo down the rate of progression by maintaining muscle slienglh for longer, leading lo ine￿ased lrfe expectsncy as well a5 a better qualrty of lrfe. We only want to fund great science - proieets that can improve the knowledge base and bring treatments that can re8ch the clinic and impfove Ihe INes of boys with DiJ¢henne Muscular Dystrophy in many ways. We want lo fund new technologies that will go on to help those affected by Du¢henne. by making the wortd accessible to them. ..CONnNUED Page 3 Alex's Trustees, Report lcontlnuedl For The Year Ended 30 June 2025 Publ1¢ B•n8fit- contlnu•d We formed a partnership wrth Duchenne UK. Dychenne UK Share the same mission and objectives 8$ Ale*s Wish and are also a parent-led charty. As a Charty Partner to Duchenne UK, we receive proie¢ts that require co-funding. All such projects have been rewewe(l extenswety by their SC￿nI￿￿ Advisory Board ISABI which is made up of some of the worfd's leading experts in Duchenne Musculai Dystrophy. They bling with them a wide range ol essential skills and knowledge basis including scientTfK, clinical and drug discovery and development. When scientists approach DLschenne UK with their ideas fof ne•V research Pfojects rt is the SAB who apply their exporience and expertise lo lesl these ideas. helping lo refine them. rf necessary. in order that Duchenne UK can make informed decisions on funding. Ale*s Wish Trustees re¥￿￿¥ all prqects pul forward before deciding upon specrfic projects to fund. We regularty send updates on prqeet perf0m)8r￿ and outcomes lo our supporter8 through a monthly newsleller as well as publish updales on ovr S￿la1 media channels. news articles on our website and submit press re￿a$8$ lo the bo¢al media companies. We have appeared on BBC East MKllan(Is Today and ITV Central. The tru$lee$ confirm that they have complied wrth the requirements of Sedion 17 of Ihg Charities Act 2011 10 have due regard lo the Charty Commission's gU￿anCe on public beI￿rt. Achlovoments and Perfomianc• M*ln Achl•v•m•nts About Duchènno Duch•nnt Sn numb•rn 1 of Ihe mosl serious genelic diseases in children 1 in 3,500 boys born with Duchgnne Worl￿￿8 2,500 boy5 affected In the UK lapprox.) 300.000 boys affected global￿ lapprox.) • 2 families every week receive a diagnosis in the UK 12 is the average agé boys requiré a wheelchair in 90% of Cases About Duch•nn• Duchenne Muscular Dystrophy is a severe. progressive genetic condition that primarity affects boys. Duchenne rosses all races. cultures. and backgrounds. Gtrfs can also be affected and make up around 1Q/(4 of diagnoses. What causos Duchenne? Duchenne is caused by a genetic muL*ion that stops the body from producing dyslrophin, a protein ￿$￿ntial for healthy muscle function. Wlthout dystrophln: Muscles weakan and break down over lime Muscles cannot repair Ihernselves propedy Strength. movement. and independence are progressivety lost Around one in three cases occurs in families wrth no prevKJus history of DL￿hen￿fj. Early signs and diagniyals: The average age of dia9nosi$ is around four yeats old. Delays in sitting and walking Difficutty keeping UP wrth peers . Sp￿h delay or frequent falls ..CONTINUED Page 4 Alex'$ Wl$h Trustees. Report Icontinued} For The Year Ended 30 June 2025 Main A¢hlovgments- ¢ontJnu•d How Duchenne progresses: Dvchenne affects everyone drfwenlfy - even SI￿1ngS with the same genetic mLrtation can experienee very drfferenl prcgressK)n. Muscle weakness usually begins in eady ¢hildht)od. affecting the hips. thighs, shoulders, and pelvis During the teenage years. weakness spieads to the am)s. lower legs and trunk Because dystrophin is also missing from the heart and lung muscles. breathing and heart function are affected Some individuals may experience learning andlor behavioural challenges . Ventilation sUPPOrt and 24-hour care is needed as the disease progresses wrth improved care, many people with Duchenne are now living into their 20$ and 305, and ongoing research and clinical trials continue to improve qualty of lrfe and oulcomu. Our Vlslon Our Vision is a world without Duchènne Muscular Oystrophy. We want a future that slops the devaslaling impact Du¢henne has on our chiklren and young arsults, a fLrtur8 where thoy can grow and prosper and fulfil their dream8. A life whero they can enjoy every day wrthout the fear of the progression this muscle wasting disease has on their bedie5. A lulure wrthoul Du¢henne would be a bright and happy future for all those affected. We need lo act quickly lo save this generation. t)oing nothing is r￿1 an option. Our boy$ and their families need to live without fear and have hope for the future. Our Mlsslon Alex's W$h exists lo end Duchenne for this generation. We do this by hatting and revorsing muscle wasting through funding groundbreaking clinical trials. supporting world55 aims lo permanenlty delelg mutslion hol$pol in the DMD gene, restoring the reading frame and enabling produclion of 8 shorter but functional dystrophin protèin, like that lound In individuals with Becker Muscular Dystrophy la milder forn of Muscular Dyslrophy). The therapy offers several advantages over existing genetic medicines, includin9 pemianenl DNA edrting. preservation of natural gone regulation. and restor*ion of a dystrophin protein three lime5 the size of micrctrdystrophin. If successful, the therapy could be suitable for approximalety 50% of boys wrth Duchenne. The funding will enable MyoGene to optimise Mltsc￿ targeting. assess dufabilty and explore potential Irealmenl regimen5 that could improve edrting effic￿ncy. The company has already engaged the FDA in the US to accelerate their abilty lo tonducl a elinical trial in DMD boys. and all being well. they should be in the clinic In 2027. Thanks to The Brothers Twst, who kindty gave a grant for £35.000 Ichvards this Project. . G5v*n £22,000 toward$ a tran$ltlonlng of care proJ•d - bettor supportlng stsndards of care for thos• transitioning from paediatric care to adult care Instrtule.. Leeds Teaching Hosprtal Princip81 Investigator." Anne-marie Childs status.. Ongoing until September 2027 ..CONTINUED Paye 7 Alex's Whh Tru$tees' Report lcontinuedl For Th¢ Year Ended 30 June 2025 Main Achlgv•m•nts- ¢ontlnu•d For young people living wrth Duchenne, the transiti'on fr(yn paediatri¢ to adult care 1$ fraught wrth challenges. This Iransrtion period is a critical lime, not just for medical management, bul also for the psychosocial support these young individuals need lo thrive as they move into adurthood. Sadly. this Iransrtion period often lacks the necessary slru¢ture and support. famil*s are left nawgating a fragmented heatthcare system with varying levels of support across the ￿Untry. The consequences ol not having a cleaf and Wel￿sUppOrted transrtion pathway are severe. Wrthout proper Iransrtion planning, young people often lace abwpl changes in their care. leading to confusion, anxiety and in some cases delerioralion in their heatth. Additionalty. the variation in services across the country means that while some re¢eive excellent care, others are left wrthout the necessary resoLsrces and support, particularty when their condrtion becomes more Complex. To address these issues, we are working in collaboration with Duchenne UK and Joining Jack (another parent- led charity in the UK) towards developing a ￿mprehenSive Iran$rtion pathway laikjred specifically for young people wrth Duchenne. This project will create resources and support systems that ensure a smoother, more effective transition into adutt care. providing both medul and psychosoc￿1 support. By working together collaboralivety wrth healthcare professKJnals. patients. and their families. this initiative WIN produce practical tools. guides. and models that can be implemented xross different heallhcore settings. . Glven £5,989 tow•rds a Post BIND ITh• Braln Involv8m•nl In OystrophlnopathleBI C04>rdlnator Inslrtule.. Univefsrty College London Principal Invèsli9alor." Francesc Munloni, Paediatric Neurologist status.. Ongoing until June 21r26 This funding supports the Ccwrdinalor post for the Brain Involvement in Dystrophinopathies IBINDI consortium which brings 10gelher 19 partnefs from Europe and Japan who recèivèd funding lor a 4-year pr￿ect from the European Commission lo address the pre¢linical and clinical aspects related to the role of dystrophin in the brain. There is a wearth of dala on gene mulalion and clinical and imaging phenotypes that has nol been fully an8ly6ed and published and this post was pul in place in Juty 2024 to comp￿1? this work and lo drivè 81ND's slralegi aims, adding greatly lo our kncmledge and Irealmenl options for the invofvement of the brain in Duchenne. Several workshops and presenlations were published in the summer of 2025 and the consortium remains committed lo improving diagnosis and treatments of brain comorbidilies In dyslrophinopalhies. . W• hav• contlnuod to ralse awareness about Duch•nn• Muscular Dystrophy. Through regular poyling across our social media plaffoms. about stories. progress. medical news, ways in which our supporters made an impacl and how they can support us in the future and are seeing an ever increasing following and engagement online. Thank you to everyone who follow5 our journey. Through our calendar of events, we have been raising the profile of our cause and engaging with existing and rw supporters. . We have $•cur•d a plp•lln• of fundralslng support and actlvlll•s over the next 12 months. In addition to the fund$ fec¢Ned during this financi* year, ￿ have seen gre* success wrth our fvndraising activities in the latter part of 2025 and into 2026. We have secured lunding from various Iwsls and foundations, induding The Brothers Tru$L Tho Hospital Saturday Fund and The D'oyty Cart• Charitable Trust. Delivered a calendar of successful and profrtable fundraising actNrties ar￿ events for our supporters to gel involved wrth, so Ihat we can continue to raise money to further mission. ..CONTINUED Page 8 Al&￿S Trustees, Report (continued) ForThe Year Ended 30 June 2025 Main A¢hiov8monl$ - continued Plus, much more about which yoij can find the delails by foll(wing us across our socol media platforms and on our website. Recent actlvltles and achiev•m•nts Over the years, we have funded a variety ol projects across a broad-speclrum from eatly-slage research through to clinical trials, funded five clinical posts lo support clinieal trial development and paI￿nt access. funded DMD Care proJecl$. as well as supporteout effective treatments. ne4V technob9￿8, improve care standards, and improvè elinical trial capacrty in the UK for the Duchenne communty and aim to gwe QOO.01)O+ per annum. ObjectNe 2.. To en9age with media and our Supporters to raisè awarenèss of DUChenr￿ Muscular Dystrophy. Attend the annual Horizons Conferenc¢$ held by Du¢henne UK to enggge with other parents affected by Duchenne Muscular Dystrophy, as well as keep abreast of lalesl progress made in the field of Duchenne. To be actively involved in workshops and rr￿lIngS alongside Duchenne UK that is focussed on improving care standards in the UK. whe￿ possible, attend national events and meètings to help l¢)bby MPS and Parfiamènl lo bring about new trealmenl8 to market as quickly a$ possible e.g. Vamorolone and Grvinoslat. Issue press releases and submit lo the I￿al piess in the East Midlands to help raise awareness about the work we are doing ènd rts impact on the local community I the re51 of the UK and lo help attract r¢ew supportOfS lo our cause. . Continue lo send monlhty updateg to our supporters wa e-newsletters. add newsworthy content to our webslto and regularly post and grow our supporter base across our socral mempany as required by sed￿n 386 of the 20(￿ Act,, or 2. the aceounls do not accord with those records.. or 3. the a¢counts do nol comply with the accounling requirements of section 396 of the 20￿ Act other than any requirement that the aceounls give a and lair vwi. which 1$ not a matter considered a8 part of an independent examinat￿n". or 4. tho accounts have not been prepared in accordance wrth the melhods and principles of the Slalemenl of Recommended Practice for accounting and reporting by charitios applicable to charities preparing their accounts in accordance wrth the Finaneial Reporting Standard applicable in the UK and Republi¢ of Ireland IFRS 1021. I have no concems and have come across no other mattefs in connection %wth the examination lo which attention should be drawn in this report in order lo en¥ts￿ a proper understanding of the ac¢ounls lo be feached. J Pelha FCCA 1210312026 Slurgess Hutchinson Chartered Certified Accounlanls 21 New Walk Leicester LE1 6TE Page 18 Alex's Wish Statement of Flnancial Actlvitles Ilncluding Income and Expenditure Account) For Tho Year Ended 30 June 2025 2026 2024 Unrestricted Restricted Total funds fund5 funds Unrestricted funds Nol•s INCOME AND ENDOWMENTS FROM: Donations and lega¢ie6 Charitable aclivilies". Fundraising activilies Investments Other 78.958 43,125 122,083 37,644 225,969 1,193 19,354 225,969 1,193 19,354 248.269 1.168 325.474 43.125 368.599 287.081 EXPENDITURE ON: Raising fund5 Charitable activilie$'. Expendrture on charitable events Adminislialive 6eTrices Support costs Separate material item ol expenditure 12.8001 {2,800) {53.7371 153.737} 153.5601 153.5601 119.3521 119.3521 1197.9891 135.0001 1232.9891 149.8421 179,5551 125,7441 1113,0001 1327.4381 135.0001 1362.4381 1268,141 {1,9641 8.125 6.161 18,940 NET INCOME NET MOVEMENT IN FUNDS RECONCILIATION OF FUNDS: Total funds brought forward TOTAL FUNDS CARRIED FORWARD {1.9641 8.125 6.161 18.940 71.832 71,832 52.892 14 69,86B 8,125 77,993 71,832 Th8 notes on pages 2110 26 fom part of these finanaal stalemenls. Page 19 Alex's Wlsh Balance Sheel As At 30 June 2025 2025 2024 Unrestricted Restri¢led Total funds funds funds Total fund$ Notes CURRENT ASSETS Debtors Cash at bank and in hand 11 20,639 68.857 20,639 16,083 8,125 76,982 68,138 89.4 8,125 97,621 84.221 Credltors: Amount• Falllng Du• Wlthln One Year 12 119,6281 119.6281 112,3891 NET CURRENT ASSETS IUABIUTIES) 69.868 8.125 77.993 71,832 TOTAL ASSETS LESS CURRENT LIA81UTIES 69,868 8,125 77,993 71,832 NET ASSETS 69,868 8,125 77.993 71.832 FUNDS OF THE CHARITY Reslrided Funds Unrgslrided Funds 8,125 69,868 71,832 TOTAL FUNDS 14 77,993 71,832 For the year ending 30 June 2025 the charitable company was eTrtrt￿d lo exemption audrt under section 477 of the Companies Act 2006 relating lo small companies. The members have not roquired the chari¢able company lo obtain an audrt in accordance wf(h 88clion 476 of the Companies Act 2006. The Iruslee8 aCknO%￿ge their responsibilrtiès for eomptying with the requirgmonls of the Acl with respect lo 8ccountin9 recor¢l$ and th• prepofation of accounts. These accounts have been prepared in accordan￿ with the provis￿n$ applicable to compani&8 5ubJ'ect to the small companies regime. On behaw of the board Mrs E J Hallam Trustee 1210312026 The notes on pages 21 to 26 fonn part of these finawal ststwnents. Page 20 Alex's Wlsh Notes to the Financial Statements For The Year Ended 30 June 2025 1. General Inforniatlon Ale￿$ is a company limited by guaranlee. incorporated in England & Wales. ￿lStered number 081161 $9 and registered chaiity number 1148845. The reg￿tered off￿e is 21 Walk, Leicesler, LE16TE. 2. Accountlng Pollcles 2.1. Ba315 of Preparatlon of Financlal Statements The financial slalemenls have been prepared in accordance wrth the Charrties SORP IFRS 102}"A¢￿￿ntlnQ and Reporting by Charit￿$.. Statement of Recommended Practice applicable lo eharrties PTepanng their accounts in accordan¢e with the Financial Reporting Standard applicable in the UK and Republic of I￿land IFRS 1021 leffeclive 1 January 20191" Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companie5 Act 2006. The charrtable company is a PublK Benefit Entrty as defined by FRS 102. 2.2. Incomlng R￿ourceS All income is recognised in the slalemenl of Financial Activities once the charity has enlrtlèment lo the fund$, rt is probable that the incomg will be received and the amount can be measured reliably. 2.3. Resources Ex￿nd•d Liabilities arè rècognised as 8<>on as thèm is a legal or construdi¥e obligat￿n committing Ihg charrty to that expenditure, rt is probable that a Iransler of economic benefrt will be fequired In settlement and the amount of the obligation can be measured ￿llabty. Expenditure is accounted fof on an accfuls basis and has been classified under headings that a99regale all c051 relating lo that category. Where costs cannot be directly attributed to patticular headings they have been allocated lo actNitie8 on a basi8 consislenl with thè u¥0 of re$ourcg3. 2.4. L•a•lng and Hlr• Purch•s• Contracts Rèntals applicable lo operating lease$ where subslanlialty all of the b8nefit$ and risks of ownership remain with the lessor are charged lo the statement of financial aclivrties as incurred. 2.5. Cash and Cash Equlv•l•nts Cash and cash equivaknls are basic financial assets and include cash in hand and deposFts held at call with bank$. other Short-term highty liquid inveslmenls that mature in no more than three months from the dale of acquisition and are readily convertible to a known amount of cash with insignif￿ant ri$k of change in value, and bank overdrafts. 2.6. Taxatlon The Charity is exempl from tax as all its income 1$ tharitable and appl￿ for Charitable purposes. 2.7. Pfjnslon$ The charitable company operates a defined pension contribution schwne. Contributions are ¢harged to the Statement of Financial Adivities as they become Payab￿ in accordance wrth the rules of the scheme. 3. In¢om• from Donatlon$ and L•gacles Page 21 Alex's N¢les to the Flnancial Statements Icontinuedl For The Year Ended 30 June 2025 2025 UnrestrS¢t•d Restrlcted Total funds funds funds Donations and grfts Grants 78.958 78,958 43,125 43,125 78.958 43,125 122.083 2024 Unrnstrlcted Rtstrlct•d Total funds fund¥ funds Donations and grfts Grants 37.644 37,644 37.644 37.644 4. Inv•stm•nt Incoffl• 2025 2024 Unr•strl¢t•d Unrestrlctod funds funds Bank interest receivable 1,193 1.168 5. Oth•r Income 2025 2024 Unrèstrlct•d Unr•strlct•d funds funds Royaty, licence and similar receNables 19,354 Page 22 Alex's Wlsh Not￿ to the Financial Ststements l¢ontinuedl For The Year Ended 30 June 2025 6. Anatysls of EX￿nd[tUr8 2026 Actlvlties Support undertaken cost$ dlrttlly {see note 71 Total Raising funds Expenditure on charitable events Administrative ¥ervi¢e¥ Support costs 2,800 53,737 2,800 53,737 53,$60 19,352 53.560 19.352 56,537 72.912 129,449 2024 A¢tSvftles Support undertaken ¢05ts dlrectly (see note 7} Total Expenditure on chantable events Adminislralive services Support costs 49.842 49,842 79,555 25,744 79,S55 25,744 49,842 105,299 155,141 7. Support Cmts 2026 Admlnlstrative s•r¥lc•s Support cost$ Total Empk)yee costs Premises expen$e$ Genofal administration 53,560 1,848 1,945 15,559 55,408 1,945 15,559 53,560 19,352 72,912 2024 Administrativè Support *er¥lces Costs Total Employee costs Premises expenses General administralKJn 79.555 2.841 7,140 15.763 82,396 7,140 15,763 79.555 25.744 105,299 Page 23 Alex'5 W￿h Notes to thg Flnan¢lal Statements l¢ontinu•d} For The Year Ended 30 June 2025 8. Ind•pend•nt Examlner's Remuneratlon 2025 2024 Independent examination of Iho financial $lalemenl$ Other assurance $grvi¢es Tax advisory services Other financial service5 2,340 2,340 2,340 2.340 9. Staff Costs Staff costs were as follows.. 2025 2024 Wages and salaries Other pension costs 52,357 1,203 77.943 1,612 53,560 79,555 No employ986 receNed employee benoffts lexcluding enybyer wnsion coslsl for the reporting period of more than £60,000. 10. Av•rag• Number ol Employe•s Average number of employees durin9 the year was.. 212024.. 31 11. Debtors 2025 2024 Due wllhln one y•ar Tradè debtors Other debtors 9.265 11.374 2,165 13,918 20.639 16,083 12. Crndltorn: Amounts Falllng Oue Withln One Y•ar 2026 2024 Trade credrtcys Other creditors AccfLbals and delefred income {1) 409 19.629 11,980 19.628 12,389 Page 24 Alex's Notes to the Flnan¢ial Statements (continued) For The Year Ended 30 June 2025 13. PensSon Commltm•nts The Charitable eompany operates a defined contribution pension scheme. The assets of the scheme are hokl separately from those of th& charitable company in an independently administered fund. During the year the ¢harge to the statement of financral actNrties in respect of defined conlribulKsn schemes was £1.20312024. £1,612). Al the balance sheet dale contributions of to {2024.. £409) were due lo the fvnd and are i￿l￿ded in credrtors. 14. Mov8m•nt In Funds As •t 1 July 2024 Asat30 Expendlturn Juno 2025 Income unr￿trICt8d funds General.. General unrestricted fvnd Ro3trl¢t•d funds The Brothers Trust The D'oyly Carte Charitable Trnsl The Hospital Salufday Fund 71.832 325.474 1327.4381 69,868 35,000 6,12S 2,000 135,0001 8.125 2.000 Total rejtrlcted fund• 43,125 135,000) 8,125 Total fund• 71.832 368.599 1362,4381 77,993 AS •t 1 July 2023 Asat30 ExpendSture June 2024 Incom• Unr05trlct•d funds General.. General unrestricted fvnd 52.892 287,081 268,1411 71.832 Total funds 52.892 287.081 1268.1411 71.832 15. Transactlons wlth Trustees During the yeai the expenses reimbursed lo the Iruslees or pahj directty to third parties were as follows.. Page 25 Al¥x's W￿h Notes to the Financial Statements Icontinuodl For Thè Year Ended 30 June 2025 2025 2024 Travel 930 1,367 16. Relat•d Party Oisclosuros There have been no related paty trans￿110￿ in the reporting period that require disclosure, except for those disclosed in the Transactions with Trustees note. 17. Company Ilmlted by guarant The company is limited by guarantee and has share caprtal. Every member of the company undertakes lo wnlribule to the assets of the company, in the event of a winding up, Such an amount as may be required not exceeding £1. Page 26 Alex's Detsiled Statement of Financial Activities (including Income and Ex￿ndItUre Account) For The Year Ended 30 June 2025 2025 2024 Total funds Total fund$ INCOME AND ENDOWMENTS FROM: Donatlons and legaclgs Donations and gffts Grants 78.958 43.125 37,644 122,083 37,644 Charltable ActIvIti￿. Fundralsing activities Fundraising aclivilies 225,969 248,269 225.969 248,269 Inv•¥trn•nts Bank interest receivable 1,193 1,168 1.193 1,168 Other Royakies and similar receivab￿$ 19,354 19.354 368.599 287.081 EXPENDITURE ON: Ralslng funds Tru¥ls and foundat￿)n¥ 12.8001 {2.8001 Charltable Actlvltles: Expendlture on charlt•ble events Annual Gow Day Annual Fundiaising 8all Our 8u3iness Community London Marathon Supercars Charity Evonl 'Be More Alex, regular giwng canwign Abseil Charity Event AGM l Annual Supporters Thank You Lunch Miss Great Britain Finals Event Football Event Loop the Loop Challenge wth AeroSparA Other sundry event costs Big Give Christmas Challenge Fashion Show 15,9601 (17,5391 {1641 14801 17.2621 15301 11,0591 13,4061 {5681 11,1321 14,7941 126,1991 13551 12,5921 14,7781 14811 11,2721 13,7741 11,0251 11,088 11,153 14081 160) {1631 ..CONTINUED Page 27 Alex's Wish Detslled Statem•nt of Flnan¢lal Actlvltles lincluding Income and Expenditure Account) (contlnuedl For Tho Ygar Ended 30 June 2025 Spring Launch Grand Prix Event Kazoo Pink Ball 131) 1931 11.2471 11101 19141 ng Walk Flot Gin Run London lo Paris Chanty Bike Ride lning It-'The Power of Resilience. talks 14,8881 1121 17.6841 12.358) 153,737) {49,8421 Admlnlstratlve sepélc Wages Empk)yers penS￿n3 152,357) 11,2031 153,5601 177.9431 11,6121 179,5551 Support costs Staff training and w8Warg Travel and subsistence Rent Computer software, consumables and maintenanee Offi'ce equipment Insurance Postage and stat￿nery Business development and ne￿Iking events Promotional malenals Websrtè and email marketing Indepèndent examinerfs fees Business services Bookkeeping and legal fees Bank charges 17831 11.0651 11.9451 13.921) 1351 16361 {1,0281 {1,S191 14,6621 16461 12,3401 1721 13741 13261 19951 11,8461 17.1401 13,6901 17131 18641 11,3491 12,0631 12,7931 18741 12,3401 14501 12571 13701 125,7441 119,352) Separate material Item of exp•ndlturn Paymènts for medical research. clinical posts and now technologwo 1232,989) 1232.9891 {113,0001 (113.000 1362.4381 1268,1411 NET INCOME 6,161 18.940 Page 28